Platelet function in coronary artery disease: effects of coronary surgery and sulfinpyrazone.
Platelet survival and plasma concentrations of beta thromboglobulin and platelet factor 4 were measured in 44 patients before and 6 months after coronary artery bypass grafting. Postoperatively, patients were randomized to receive sulfinpyrazone, 800 mg/day, or placebo. Preoperatively, platelet survival was significantly shorter than normal, and plasma concentrations of both platelet-specific proteins were significantly elevated. Postoperatively, all three indexes of platelet function tended to become normal, but these changes were statistically significant only in patients treated with sulfinpyrazone. Postoperative exercise testing correlated significantly with plasma concentrations of beta thromboglobulin and platelet factor 4 measured preoperative and postoperative. These results are consistent with reports of the effects of sulfinpyrazine on platelet involvement in other conditions, and suggest that the drug reduces platelet activation and inhibits actual destruction. The results also show a relationship between abnormalities of platelet function and an index of postoperative myocardial ischemia.
D000787:Angina Pectoris / Q000097:blood / Q000628:therapy; D001792:Blood Platelets / Q000502:physiology*; D002986:Clinical Trials as Topic; D001026:Coronary Artery Bypass; D003326:Coronary Circulation / Q000187:drug effects; D003327:Coronary Disease / Q000097:blood* / Q000628:therapy; D004311:Double-Blind Method; D006801:Humans; D010978:Platelet Factor 4 / Q000502:physiology; D010979:Platelet Function Tests; D011897:Random Allocation; D013442:Sulfinpyrazone / Q000627:therapeutic use*; D001620:beta-Thromboglobulin / Q000502:physiology
D001620:beta-Thromboglobulin; D010978:Platelet Factor 4; D013442:Sulfinpyrazone